Inflammation in Obese Parturients: Surgical Outcomes After Elective Caesarean Section

Sponsor
University of Manitoba (Other)
Overall Status
Completed
CT.gov ID
NCT01836315
Collaborator
(none)
25
1
11
2.3

Study Details

Study Description

Brief Summary

Hypothesis: The investigators propose that obese parturients will have an increased inflammatory response and a decreased anti-inflammatory response to the surgical and anesthetic insult of caesarean section and that this will be associated with a higher rate of perioperative complications, as compared to non-obese parturients.2 Background: Obese patients exhibit higher levels of inflammatory markers than non-obese patients. Furthermore, obese patients have a higher incidence of perioperative complications, especially wound infections, and this is well documented in the caesarean section population. The pregnant population is unique as a result of the immunologic changes that occur at baseline, and an increase in pro-inflammatory markers is seen in serum and in placental tissue of obese subjects, and has been demonstrated to correlate with adverse fetal outcomes.

Specific Objectives: To determine the baseline levels of three established markers of inflammation in term pregnant obese and non-obese patients (defined by a BMI > and < 35 kg/M2 respectively), and examine how they change in response to the stress of surgery/anesthesia. The investigators will correlate the inflammatory response with the incidence of postoperative wound infections.

Methods: Patients will be recruited to the study prior to the planned caesarean section. Blood samples for inflammatory marker levels will be performed preoperatively, immediately postoperatively, and at 24 hours postoperatively. Samples will be analyzed for pentraxin-3 (a relatively novel inflammatory marker), C reactive protein (CRP) (a well-known and clinically relevant inflammatory marker), and interleukin-10 (IL-10) (an established anti-inflammatory marker). Plasma will be analyzed by ELISA to determine levels of each biomarker. Patient charts will be reviewed to determine which patients have experienced surgical complications in the 30 days postoperatively. Surgical complications will then be correlated with the measured levels of inflammatory markers.

Assuming that the levels of inflammatory cytokines in obese patients will be 15% higher in obese parturients and assuming an alpha error level of 5% and a beta error level of 20%, the investigators would need to study 18 patients per group to prove our hypothesis that inflammatory cytokine levels are correlated with postoperative infections. The investigators plan to study 20 patients per group to account for a potential patient attrition rate of 10% during the study.

Significance/Importance: The connection between obesity and dysregulation of the perioperative inflammatory response has not been well established nor has perioperative inflammation in the obese population been linked to the observed increased in perioperative morbidity. The investigators hope to demonstrate these connections and hopefully will be able to identify at risk patients earlier, and in a subsequent study intervene to reduce the risk of postoperative wound infections with pharmacokinetically targeted antimicrobial prophylaxis.

Condition or Disease Intervention/Treatment Phase
  • Other: Observational Study

Study Design

Study Type:
Observational
Actual Enrollment :
25 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Inflammation in Obese Parturients: Surgical Outcomes After Elective Caesarean Section
Study Start Date :
Jan 1, 2013
Actual Primary Completion Date :
Dec 1, 2013
Actual Study Completion Date :
Dec 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Obese

Defined by a BMI >35 kg/M2

Other: Observational Study
Other Names:
  • Observational Study Only
  • Non-Obese

    Defined by a BMI <35 kg/M2

    Other: Observational Study
    Other Names:
  • Observational Study Only
  • Outcome Measures

    Primary Outcome Measures

    1. Level of inflammatory biomarkers [2 days]

      Levels of inflammatory biomarkers (specifically pentraxin-3 (a relatively novel inflammatory marker), C reactive protein (CRP) (a well-known and clinically relevant inflammatory marker), and interleukin-10 (IL-10) (an established anti-inflammatory marker)).

    Secondary Outcome Measures

    1. Incidence of postoperative wound infections [28 days]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Inclusion Criteria:
    • obese (defined as a body bass index (BMI) of greater than 35 kg/M2) or non-obese (BMI <35 kg/M2)

    • female

    • Over 18 years of age

    Exclusion Criteria:
    • Any acute or chronic medical illness acquired before or during pregnancy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Health Sciences Center Winnipeg Manitoba Canada R3A1R9

    Sponsors and Collaborators

    • University of Manitoba

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr. Duane Funk, Assistant Professor, University of Manitoba
    ClinicalTrials.gov Identifier:
    NCT01836315
    Other Study ID Numbers:
    • B2012:123
    First Posted:
    Apr 19, 2013
    Last Update Posted:
    Dec 10, 2013
    Last Verified:
    Dec 1, 2013
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 10, 2013